SCHEMBL4548905

SCHEMBL4548905

CNc1cc(Oc2ccc3c(C(=O)Nc4ccc(OC)nc4)cccc3c2)ccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.74
FGFR1 P11362 1/20 0.55
CYP3A4 P08684 3/20 0.53
CYP2D6 P10635 2/20 0.53
AURKA O14965 1/20 0.52
LCK P06239 1/20 0.52
CSF1R P07333 1/20 0.52
MET P08581 1/20 0.52
BRAF P15056 1/20 0.52
FLT1 P17948 1/20 0.52
FGFR2 P21802 1/20 0.52
FLT4 P35916 1/20 0.52
TEK Q02763 1/20 0.52
AURKB Q96GD4 1/20 0.52
MEN1 O00255 1/20 0.52
CASP3 P42574 1/20 0.52
KMT2A Q03164 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748198 0.90 KDR (0.84) KDRFGFR1CYP3A4CYP2D6AURKA
SCHEMBL4548899 0.88 KDR (0.75) KDRFGFR1CYP3A4CYP2D6
SCHEMBL5739608 0.86 KDR (0.78) KDRFGFR1CYP3A4CYP2D6AURKA
SCHEMBL4548897 0.86 KDR (0.84) KDRFGFR1CYP3A4CYP2D6AURKA
SCHEMBL4548898 0.85 KDR (1.00) KDRFGFR1AURKALCKCSF1R
SCHEMBL4548895 0.83 KDR (0.82) KDRFGFR1CYP3A4CYP2D6AURKA
SCHEMBL4548901 0.83 KDR (0.79) KDRFGFR1CSF1RFGFR2
SCHEMBL4548900 0.83 KDR (0.76) KDRFGFR1FLT1FGFR2FLT4
SCHEMBL4548896 0.83 KDR (0.78) KDRFGFR1AURKALCKCSF1R
SCHEMBL4548910 0.82 KDR (0.84) KDRFGFR1AURKALCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FGFR1 9/4885CYP3A4 348/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FGFR1 9/4885CYP3A4 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.